Abstract
Chronic obstructive pulmonary disease (COPD) is a complex, multicomponent disease at the clinical, cellular, and molecular levels. Over the past few years there has been a growing interest in the field of biomarkers in COPD and a large number of studies have evaluated potential candidate molecules in different patient settings. Data on systemic biomarkers from large cohorts, including the well-characterized population of the ECLIPSE study, are now available and provide exciting information on the association of biomarkers with clinically important outcomes, including exacerbations, hospitalizations and mortality. Moreover, recent research has provided proof for the existence of distinct "systemic inflammatory" phenotypes. This review summarizes the currently available evidence on systemic biomarkers in COPD, providing clinically relevant information on the possible role of systemic biomarkers in the evaluation of disease activity and severity, phenotypes, outcomes, COPD exacerbations and treatment response and guidance. Despite the fact that no single biomarker is currently ready to characterize sufficiently the status of COPD patients, guide treatment options, and predict future events, recent studies have rendered our current knowledge definitely more advanced than a few years ago and the possible use of biomarkers in the diagnosis and management of COPD patients looks even more promising.
Keywords: COPD, biomarkers, blood, phenotypes, exacerbations, management
Current Drug Targets
Title:Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Volume: 14 Issue: 2
Author(s): Konstantinos Kostikas, Petros Bakakos, Spyros Papiris, Daiana Stolz and Bartolome R. Celli
Affiliation:
Keywords: COPD, biomarkers, blood, phenotypes, exacerbations, management
Abstract: Chronic obstructive pulmonary disease (COPD) is a complex, multicomponent disease at the clinical, cellular, and molecular levels. Over the past few years there has been a growing interest in the field of biomarkers in COPD and a large number of studies have evaluated potential candidate molecules in different patient settings. Data on systemic biomarkers from large cohorts, including the well-characterized population of the ECLIPSE study, are now available and provide exciting information on the association of biomarkers with clinically important outcomes, including exacerbations, hospitalizations and mortality. Moreover, recent research has provided proof for the existence of distinct "systemic inflammatory" phenotypes. This review summarizes the currently available evidence on systemic biomarkers in COPD, providing clinically relevant information on the possible role of systemic biomarkers in the evaluation of disease activity and severity, phenotypes, outcomes, COPD exacerbations and treatment response and guidance. Despite the fact that no single biomarker is currently ready to characterize sufficiently the status of COPD patients, guide treatment options, and predict future events, recent studies have rendered our current knowledge definitely more advanced than a few years ago and the possible use of biomarkers in the diagnosis and management of COPD patients looks even more promising.
Export Options
About this article
Cite this article as:
Kostikas Konstantinos, Bakakos Petros, Papiris Spyros, Stolz Daiana and R. Celli Bartolome, Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020005
DOI https://dx.doi.org/10.2174/1389450111314020005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Herbicide Glyphosate and Its Apparently Controversial Effect on Human Health: An Updated Clinical Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Gene Therapy for Osteoinduction
Current Gene Therapy